WASHINGTON, Sept. 10,
2024 /PRNewswire/ -- Novel device-based therapies may
overcome limitations of pharmacologic therapies for some patients
living with heart failure (HF), indicating that a synergistic
approach between the two therapies is ideal for implementation of
guideline directed medical therapy (GDMT). The Heart Failure
Society of America (HFSA) Scientific Statement: Update on Device
Based Therapies in Heart Failure, published today in
the Journal of Cardiac Failure (JCF), provides a
state-of-the-art scientific overview and update of the rapidly
evolving field of device-based therapies for HF, including a
clinical pathway to implementation of these technologies alongside
pharmacologic therapies.
While tremendous advances have been made to reduce
hospitalizations and improve outcomes for patients with HF in the
past decade, the residual risk on optimized guideline directed
medical therapy (GDMT) remains on par or worse than other major
cardiovascular diseases. Some established medical devices, such as
implantable cardioverter-defibrillator (ICD) and cardiac
resynchronization therapy (CRT), are widely used alongside
pharmacologic therapies. However, in some high-risk patients that
exhibit an intolerance for certain drugs, novel device therapies
may prove highly effective in producing promising outcomes.
The Update on Device Based Therapies in Heart
Failure is scientific statement defines how these novel
device therapies may bridge current gaps in HF treatment and
outcomes and proposes a clinical pathway to implement FDA approved
device-based therapies that align with current HF management
workflow.
"Our consensus document defines the unmet need in chronic heart
failure and the important role of device-based therapies in
bridging heart failure gaps," said co-lead author Jerry D. Estep, M.D., FACC, FASE (Division
Chair, Cardiovascular Medicine, Cleveland Clinic Florida). "We
provide detailed information on the different categories of heart
failure devices and use considerations based on associated
contemporary outcome data. We hope our document will improve
patient outcomes by providing a clinical framework to guide
implementation of current and future FDA approved device-based
therapies."
Novel FDA-approved devices for consideration in the statement
include cardiac contractility modulation (CCM), baroreflex
activation therapy (BAT), valve interventions with transcatheter
aortic valve replacement, mitral valve edge-to-edge repair,
tricuspid repair, CardioMEMS pulmonary artery pressure monitoring,
and HeartMate [HM] 3 left ventricular assist device [LVAD].
The Update on Device Based Therapies in Heart
Failure scientific statement proposes a clinical pathway
to implementation that involves the consideration of device-based
therapies following a persistence of NYHA class II or above
symptoms after 3-6 months of pharmacological GDMT and CRT. It also
suggests that there must be improved systems of evaluating
appropriate patient populations for these therapies, as they may be
underutilized, especially in cases where patients may be eligible
for more than one device-based therapy. Overall, the scientific
statement suggests that a personalized approach to selecting
therapies when implementing GDMT will most benefit patient
outcomes.
The Heart Failure Society of America (HFSA) Scientific
Statement: Update on Device Based Therapies in Heart
Failure is available online in the JCF at
www.onlinejcf.com.
View the Top Ten Key Takeaways.
View all HFSA published scientific statements, guidelines and
other clinical documents.
DOI: https://doi.org/10.1016/j.cardfail.2024.07.007
About the Heart Failure Society of America
The Heart Failure Society of America, Inc. (HFSA) represents the
first organized effort by heart failure experts from the Americas
to provide a forum for all those interested in heart function,
heart failure, and congestive heart failure (CHF) research and
patient care. The mission of HFSA is to provide a platform to
improve and expand heart failure care through collaboration,
education, innovation, research, and advocacy. HFSA members include
physicians, scientists, nurses, nurse practitioners, pharmacists,
trainees, other healthcare workers and patients. For more
information, visit hfsa.org.
About the Journal of Cardiac Failure
The Journal of Cardiac Failure (JCF) publishes the
highest quality science in the field of heart failure with a focus
on diversity, equity, and inclusion, mentorship, multidisciplinary
partnerships, and patient-centeredness. Published papers span
original investigator-initiated work to state-of-the-art reviews,
guidelines and scientific statements, expert perspectives, early
career and trainee spotlight pieces, patient and patient-partner
narratives. JCF also emphasizes the power of language and
prioritizes innovative approaches to dissemination of published
work to reach and impact the broader heart failure community.
Media Contact: Laura Poko,
301-798-4493, ext. 226, lpoko@hfsa.org
View original content to download
multimedia:https://www.prnewswire.com/news-releases/the-case-for-integrating-novel-device-based-therapies-into-guideline-directed-medical-therapy-for-the-treatment-of-heart-failure-302244194.html
SOURCE Heart Failure Society of America